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ABSTRACT
Keratinocyte-derived carcinomas represent the most common type of malignancy
worldwide, and while surgical removal is a first-line therapy, surgery may be
impractical for certain patients and does not completely eliminate risk of recurrence.
Previous studies have demonstrated the advantages of biodegradable poly(lactic
acid)-hyperbranched polyglycerol non-bioadhesive nanoparticles (NNPs) and
bioadhesive nanoparticles (BNPs) as chemotherapeutic drug delivery vehicles for
the treatment of internal solid tumors. We are now investigating the use of this
delivery system for the treatment of cutaneous malignancies, with the goal of
maximizing drug efficacy while minimizing systemic effects and treatment-associated
morbidity. After topical application of fluorescent dye-loaded NNPs to the intact skin
of mice, epidermal penetration of the NNPs to the dermal-epidermal junction and
accumulation within hair follicles was observed at time points ranging from 4 to 72
hours. Using the PDV squamous cell carcinoma (SCC) murine model, both dyeloaded NNPs and BNPs exhibited a dose- and time- dependent association with
PDV cells in vitro by flow cytometry, and BNPs had increased association with cells
compared to NNPs. Confocal microscopy confirmed internalization of NPs by cells.
Camptothecin (CPT)-loaded NNPs and BNPs were developed; these particles
contained 5% by weight CPT. There was no significant difference in effect on PDV
cell proliferation in vitro among CPT, CPT/NNP, and CPT/BNP treatment groups. A
pilot study using subcutaneously transplanted PDV tumors showed effective and
complete destruction of the tumor after intratumoral injection of CPT/BNP. A
subsequent study using an increased frequency of treatment and lower
concentration of CPT compared CPT/intralipid (CPT/IL), CPT/NNP and CPT/BNP
injections and showed prolonged survival in all CPT groups compared to control, and
a trend toward prolonged survival in NNP and BNP groups compared to CPT/IL.
However, none of the three treatments fully eliminated tumor burden in treated mice,
suggesting that a higher concentration of drug may be optimal. Overall, our results
indicate that both NNPs and BNPs rapidly associate with PDV tumor cells, and in
vitro drug delivery is not inhibited by NP encapsulation. Further studies are needed
to optimize the method, concentration, and frequency of nanoparticle and drug
delivery to effectively and consistently treat SCC tumors.
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BACKGROUND

Skin cancer epidemiology and treatment
Cancers of the skin are the most common malignancies worldwide. Each
year in the US alone, there are over 5.4 million new diagnoses of skin cancer,
resulting in over 10,000 deaths.1–3 Skin cancers may be categorized into
melanoma and non-melanoma skin cancers. Non-melanoma skin cancers are
further sub-divided into (1) keratinocyte-derived carcinomas (KDCs), which
include basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), and (2)
non-keratinocyte tumors such as Merkel cell carcinoma and angiocarcinomas of
cutaneous vessels, among others. KDCs comprise the vast majority of skin
cancer diagnoses, and the incidence of KDCs is rising.4 Most common in fairskinned individuals, KDCs largely arise secondary to DNA damage caused by
ultraviolet radiation (UVR) exposure, but they may also be triggered by
immunosuppression and/or viruses such as human papillomavirus (HPV).5–8 Both
BCCs and SCCs can be destructive via local invasion. SCCs carry an additional
risk of metastasis that is estimated at 2-5%, but can be as high as 45% for locally
recurrent tumors on the face.9–13 Actinic keratoses (AK) are precancerous lesions
and precursors to SCC, and present as rough, scaly macules on the skin.14 AKs
most commonly arise in fair-skinned individuals with a history of extensive,
chronic sun exposure. Fortunately, KDCs are highly curable with early detection
and definitive treatment, and treatment can prevent the progression of AKs to
cancerous lesions.15,16
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For many patients with KDCs, in-office surgical procedures are effective
first-line treatments. These procedures include conventional excision and Mohs
micrographic surgery (MMS). However, surgery may not be appropriate or ideal
for all patients. Patients with lesions in areas that are surgically difficult to close,
such as on the scalp or face, may require complicated surgical flaps or grafts to
achieve acceptable cosmetic results. Grafts may also be associated with
complications such as infection and skin discoloration. SCC tumors that cover
large surface areas can be seen in patients as a result of severe solar actinic
damage, often requiring sizeable excisions that may be destructive, disfiguring,
and even functionally debilitating, and they may also necessitate the use of grafts
for wound closure. Other patients may prefer alternative, non-surgical methods of
treatment for convenience, cost, or other personal preferences.
Notably, KDCs impose a significant cost burden on healthcare systems.
Treatment costs of KDCs total over $8.1 billion per year in the US, in large part
due to surgical procedures.17 MMS is a staged excision technique that is most
commonly used on the head and neck and involves histopathologic examination
after each step of excision in order to maximize the preservation of normal tissue
and anatomy and minimize recurrence rates. Despite its lower rates of tumor
recurrence, relative to more simple surgical procedures, MMS is particularly
costly and time consuming.18 The average cost of MMS is $1,000-2,000 per
treatment, depending on tumor size and number of excision stages.19,20 Despite
these high costs, current surgical treatment methods still do completely eliminate
risk of recurrence in vast majority of cases.21 In light of these limitations,
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nonetheless, there is a demand for more cost-effective and clinically practical
non-surgical alternatives to improve the treatment of KDCs.

Alternative therapies for skin cancer treatment
Several non-surgical therapies are also available for superficial KDCs;
however, these have limited efficacy, a higher rate of recurrence, and are not
effective in the treatment of full-depth or invasive KDCs. Radiation therapy may
be used for patients who are unwilling or unable to undergo surgery, with a 5year recurrence rate of 5-20%.22,23 However, patients may experience significant
adverse effects, including radiation dermatitis, epidermal atrophy, and secondary
cutaneous malignancies.24 Radiation therapy is also less favorable for younger
patients, as the risk of late-onset adverse effects increases with time. Destruction
by curettage and cautery/electrodessication (C&D) involves the removal of the
visible tumor by curettage, followed by the use of cautery or electrodessication to
destroy 1 mm of tissue at the tumor margins.25 C&D is recommended only for
treatment of small (<1 cm), low-risk KCs, and is associated with 5-year
recurrence rates between 3-19%.26–29
Cryotherapy, which involves the freezing of skin lesions with liquid
nitrogen, is primarily used in the treatment of AKs and superficial KDCs. While
the method can be effective in eliminating full-thickness KDCs, its utility is
significantly hindered by the inability to assess treatment margins for residual
malignanancy.30–33 Moreover, there is no standardized method of treatment
regarding duration and number of cycles of freezing and thawing. Poor cosmetic
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outcomes are also of concern, due to common complications including blistering,
pigmentary changes, and edema.25 Post-treatment scar formation can present
additional risk due to the potential obscuration of recurrent lesions, and other
complications may also include hemorrhage and, rarely, nerve damage.
Diclofenac, ingenol mebutate, and trichloroacetic acid are topical
medications that may be used to treat pre-cancerous AKs, but are not sufficiently
effective in eliminating KDCs.34–38 Imiquimod is a topical immunomodulator that
stimulates the immune system to react to and destroy tumor cells and may be
used in the treatment of superficial KDCs. Topical chemotherapeutic drugs, such
as 5-fluorouracil (5-FU), also may also be used to treat superficial KDCs by
interfering with DNA synthesis in actively dividing cells.39
Similarly, topical photosensitization with δ-aminolevulinic acid (δ-ALA)
followed by photodynamic therapy (PDT) can also be used to treat superficial
BCCs and SCC in situ.40 δ-ALA is an amino acid involved in the porphyrin
synthesis pathway. It induces photosensitization of epidermal cells via metabolic
conversion of δ-ALA to protoporphyrin IX, which accumulates in the skin and
produces a cytotoxic photodynamic reaction. However, δ-ALA/PDT is associated
with pain, and disease recurrence rates may exceed 50%.41–43 Pulsed dye laser
surgery has been reported as an alternative treatment for BCCs and SCCs, but it
is not FDA-approved for this indication and is less effective than surgery.44,45
Thus, while these non-surgical treatments have some efficacy, they may not be
appropriate for deeper or invasive lesions, and success rates may be significantly
less than that of surgical treatments.
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Despite the abundance of FDA-approved chemotherapeutic agents, 5-FU
is the only commonly used chemotherapy in the topical treatment of KDCs. There
are a number of challenges that limit the efficacy and practicality of
chemotherapeutic drugs for KDC therapy. Small molecule chemotherapeutic
agents may rapidly disperse from the application or injection site after
administration, resulting in low concentrations of drug at the site of interest.
Diffusion into the bloodstream via the dense vasculature within tumors can also
lead to significant systemic toxicity. Thus, achieving high local concentrations
and efficacy without systemic toxicity is a major concern. Given the efficacy and
relative safety of current surgical treatments, a novel chemotherapy-based
treatment would need to both be highly effective and have an excellent safety
profile to be practical for clinical use. Here, we propose the use of polymer
nanoparticles in the delivery of chemotherapeutic agents for the treatment of skin
cancer.

Polymer nanoparticles: applications and advantages
Polymer nanoparticles (NPs) is an umbrella term that primarily refers to
polymer-based nanospheres and nanocapsules.46,47 Polymers are commonly
used in drug delivery and medical applications due to their favorable
biocompatibility and inert nature which result in excellent safety and tolerability.
Moreover, NPs have a number of important characteristics that make them
attractive and effective for drug delivery. These include the enhanced
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permeability and retention (EPR) effect, increased surface area, biodegradability,
and controlled-release of drug.
The enhanced permeability and retention (EPR) effect refers to the
preferential accumulation of macromolecules and nanoparticles in tumors
compared to normal tissue (Figure 1).48–50 The EPR effect occurs due to a
combination of irregular tumor vascular structure, high vascular density and
permeability, and defective lymphatic drainage.51,52 In tumor angiogenesis,
vascular endothelial cells proliferate out of proportion to pericytes, which are
responsible for blood vessel stability. As a result, blood vessels, which normally
have junctions less than 10 nm in size, become highly porous with pores greater
than 100 nm in diameter.48 The resulting vascular permeability allows for
extravasation of macromolecules such as NPs into the interstitial space of the
tumor.53 In normal tissue, the lymphatic system is able to clear similarly sized
macromolecules from the interstitium. However, tumors have impaired
lymphatics which prevent effective drainage and may therefore allow the
accumulation of NPs in the interstitium and prolonged contact of NPs with tumor
cells.54
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Figure 1. The enhanced permeability and retention (EPR) effect describes
the properties of tumor structure that permit the accumulation of
macromolecules, such as polymer nanoparticles, in the tumor interstitium.
The EPR effect is one of the hypotheses regarding the efficacy of nanoparticles
for drug delivery in tumor therapy.
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The size of NPs also contributes to reduced systemic toxicity. While the
term NP may refer to any particle in the 1-1000 nm size range, NPs are most
commonly between 100-500 nm.47,55 With a diameter larger than that of normal
vessel junctions, NPs are typically unable to penetrate normal vasculature,
resulting in minimal concentrations of drug reaching normal tissues such as skin,
heart, and lung.51 NPs are primarily removed from the circulation by hepatic
excretion and through the mononuclear phagocytic system. They are excreted in
the bile and by phagocytosis via Kupffer cells (stellate macrophages) in the liver,
macrophages in the spleen, and by local macrophages at the point of entry.56,57
The structure of NPs also increases surface area compared to free drug
alone. A greater surface area results in an increased likelihood of interaction with
other molecules or cells. Modification of the surface of NPs can affect the
characteristics and behavior of NPs, and these effects can be amplified by an
increased surface area. For instance, antibodies can be used on NPs to target
specific cellular proteins and cells, while more non-specific chemical alterations,
resulting in more reactive or inert terminal structures, can increase or decrease
the likelihood of interactions with cellular proteins.58–60
Due to their biodegradable nature, NPs allow for the controlled-release of
their contents.61,62 Notably, nanoparticle controlled release can be attributed to
two effects, degradation and erosion. Degradation refers to the chemical reaction
of bond-cleavage, while erosion refers to the physical processes of dissolution
and diffusion. Poly(esters) such as poly(lactic acid) are chemically degraded by
hydrolysis, however it is hypothesized that most biodegradable polymers
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undergo breakdown by a combination of both processes.62 As the polymer
degrades over time, encapsulated drug is released from the NPs. Compared with
repeated administrations of free drug that would result in alternating peaks and
troughs of local concentration, an NP-encapsulated delivery system would
provide a sustained release of drug into the surrounding tissue over an extended
period of time. The latter results in a more stable local concentration of drug,
which can reduce toxicity associated with temporary peaks in concentration. In
conjunction with the EPR effect, NPs can also produce a depot effect, allowing
for maximal local concentration while minimizing systemic toxicity.
Poly(lactic)-acid (PLA) is a polymer that is commonly used in NPs due to
its excellent safety profile, biodegradability, controlled-release, and nonimmunogenic properties.63,64 It can be sourced from renewable resources such
as corn starch and sugarcane, among other materials, making it highly
sustainable.65 Given its favorable properties, PLA is used in a variety of medical
applications, including implantable screws, plates, and rods.66–68 In combination
with polyglycolic acid, PLA is also used to create dissolvable sutures.
Importantly, the surface of polymer NPs can be altered to affect its biochemical
properties. Polyethylene glycol (PEG) is a surface coating that was previously
commonly used due to its low toxicity and low immunogenicity; however,
synthesizing PEG-coated NPs with sufficient density of surface PEG chains can
be difficult.69,70 In this study, we use PLA with a hyper-branched polyglycerol
coating (PLA-HPG). While HPG provides similar advantages as PEG in reducing
attachment of NPs to cellular proteins, there are a few important distinctions.
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HPG is more hydrophilic than PEG, which is advantageous for the encapsulation
of poorly soluble, hydrophobic drugs. In addition, the hyperbranched structure of
HPG provides enhanced coverage of the NP surface compared to PEG. The
multiple hydroxyl groups in HPG also allow for the attachment of multiple ligands
per HPG.
While PLA-HPG NPs are relatively inert, incubation of non-bioadhesive
NPs (NNPs) with sodium periodate can produce aldehyde-rich NPs, termed
bioadhesive NPs (BNPs), which are more biologically reactive. This chemical
reaction with sodium periodate involves the conversion of vicinal diols to
aldehydes on the surface of NPs.71 These aldehydes may then readily form
covalent bonds, such as Schiff-base bonds, with amines on cellular proteins. The
result is improved adhesion of NPs to cell surfaces and subsequently increased
uptake by cells. The use of NNPs may result in decreased internalization by
cells, while BNPs may enhance internalization via surface interactions.71

Use of nanoparticles in therapeutics
Given the aforementioned characteristics, NPs offer a number advantages
that are useful for drug delivery. In particular, the use of NPs in cancer therapy
has been an important area of study, as chemotherapeutic and cytotoxic
anticancer agents often have significant systemic toxicity. A few NP-based
cancer therapeutics are already commercially available. Genexol-PM (Samyang
Biopharmaceuticals, Seongnam, South Korea) is a polymeric NP micelle
formulation for the delivery of paclitaxel to treat metastatic breast cancer. The
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NP-based formulation not only decreases the systemic toxicity associated with
paclitaxel, but also increases the maximum tolerated dose of paclitaxel to greater
than twice that of Taxol.72–74 Oncaspar (Enzon, Piscataway, NJ, USA) is a
modified, PEGylated form of the enzyme L-asparaginase, and is used to treat
acute lymphoblastic leukemia.34 In clinical trials, it reduced the frequency of
formation of anti-asparaginase antibodies by hindering detection of the antigen
by the immune system.76,77
In recent studies from Mark Saltzman’s research group, NPs have also
been effectively utilized as a drug delivery platform to target difficult-to-treat
malignancies in mouse models. To target glioblastoma, Sawyer et al. used
polymer NPs containing the chemotherapeutic drug camptothecin in conjunction
with convection-enhanced delivery (CED).78 The efficacy of this combination,
which resulted in prolonged survival of glioblastoma-bearing mice, was
hypothesized to be a result of an increased duration of exposure to the drug and
an increased volume into which drug was distributed via CED. In another study
from the same group, Deng et al. determined that BNP-encapsulation of
epithilone B enhanced survival of mice with intraperitoneal uterine serous
carcinoma tumors, likely due to enhanced interaction with mesothelial cells and
improved retention of NPs intraperitoneally.79

Murine SCC model and chemotherapeutic drugs
In our assessment of NP efficacy in the treatment of KDCs, we chose to
focus our study on SCC, given its relative propensity for metastasis in humans
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and increased mortality compared to BCC. In addition, because SCCs can
present as widespread lesions that cover large surface areas due to progressive,
severe actinic damage or immunosuppression, these cases also stand to benefit
the most from a non-surgical therapeutic strategy. We sought an SCC tumor
model that could be reliably transplanted, producing tumors that were consistent
in size and number. Additionally, our ideal model would produce rapidly
progressive tumors, thereby allowing us to most efficiently conduct our
experiments. As such, we selected the PDV SCC murine cell line for our study.
This cell line was originally derived by chemical carcinogensis via treatment of
epidermal cells by 7,12-Dimethylbenz[a]anthracene (DMBA).80
Camptothecin (CPT) is a DNA-topoisomerase I inhibitor and powerful
cytotoxic agent. CPT is a naturally occurring compound derived from the
Camptotheca acuminata plant, and it was initially discovered in a screen of plant
extracts for antitumor activity.81 CPT binds to the topoisomerase I and DNA
complex resulting in a stable ternary complex that prevents DNA ligation.82 This
results in a double-stranded DNA break and subsequent apoptosis. While CPT
analogues such as topotecan and irinotecan have had clinical success, it is not
used clinically due to severe adverse effects, including bladder toxicity.83–85 CPT
can have a closed- or open- ring conformation, depending on pH (Figure 2). The
closed ring or lactone conformation is stable at pH < 5.5 and is the active form of
the molecule, while the open ring conformation is more soluble but has poor
activity.86,87 Conversely, bladder toxicity results from exposure of CPT to the low
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pH in the urine, which results in a conformational change of CPT to the closed
ring form.
We selected CPT for our preliminary studies for two primary reasons.
First, it was important for proof of principle that we select a particularly cytotoxic
agent to assess whether our delivery system could be effective at altering the
bioavailability of the drug. Second, CPT is hydrophobic and poorly soluble, which
makes it an excellent candidate for encapsulation using PLA-HPG. While these
properties make CPT difficult to use clinically, they are ideal qualities for our
study. Encapsulation in NPs may improve the clinical usability of CPT by
concentrating its cytotoxic effects locally and decreasing systemic toxicity.
Moreover, NP encapsulation may structurally stabilize the drug, delaying
inactivation at physiologic pH and enhancing the efficacy of CPT. For similar
reasons, we also chose to screen paclitaxel (PTX), a powerful and poorly soluble
chemotherapeutic agent that is associated with significant systemic toxicity. As
previously mentioned, PTX is not only employed directly as a chemotherapeutic
drug, but it is also used in FDA-approved NP-based therapeutics (Genexol-PM).
To study the behavior of NPs in our murine carcinoma model, we
encapsulated fluorescent dye in NNPs and BNPs and characterized their
association with cultured PDV SCC cells and dispersion after intratumoral
injection. We subsequently developed CPT-encapsulated NNPs (CPT/NNP) and
BNPs (CPT/BNP) and assessed their cytotoxicity and anti-tumor efficacy in
comparison to CPT in vehicle to determine whether NNPs or BNPs may be an
effective chemotherapeutic drug delivery platform for the treatment of SCC.
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Figure 2. The structure of camptothecin varies depending on the pH of its
environment. The active lactone structure (left) is present in acidic solutions,
with pH < 5.5. At physiological pH, the inactive open conformation (right)
predominates.
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STATEMENT OF PURPOSE
Prior work has shown that NPs may be an effective drug delivery system
in the treatment of malignant tumors, and BNPs may be particularly efficacious.
This may be due to advantageous properties such as controlled release, depot
effect, and increased association with tumor cells compared with non-malignant
cells. Our objective is to assess the properties and anti-tumor efficacy of
chemotherapy-loaded NPs in a SCC mouse model.

HYPOTHESIS
NP-encapsulation of a chemotherapeutic agent will allow for the safe and
effective treatment of cutaneous malignancies by maximizing local concentration
of drug and minimizing systemic toxicity and will have superior anti-tumor efficacy
compared to chemotherapeutic agent alone due to advantages which include the
EPR effect and gradual release of drug. Given their surface properties, BNPs
may have superior efficacy compared to NNPs.

SPECIFIC AIMS
1) To characterize NP association with PDV SCC cells and transplanted PDV
SCC tumors in vitro and in vivo using dye-encapsulated NPs
2) To assess the efficacy of chemotherapy-encapsulated NPs in the
treatment of established SCC tumors in mice and compare the relative
efficacies of drug/NNP, drug/BNP, and drug in vehicle.
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METHODS
Synthesis of NNPs and BNPs
Materials. Poly(D,L-lactic acid) (Mw = 20.2 kDa, Mn = 12.4 kDa) was obtained
from Lactel Absorbable Polymers (Birmingham, AL). Anhydrous 1,1,1trishydroxymethylpropane, KOCH3, 10x phosphate-buffered saline (PBS),
Na2SO3, and NaIO4 were obtained from Sigma Aldrich (Darmstadt, Germany).
The 1,10-dioctadecyl-3,3,30,30-tetramethylindodicarbocyanine, 4chlorobenzenesulphonate salt (DiD) was obtained from Thermo Fisher Scientific
(Waltham, MA).
HPG synthesis. HPG was synthesized by anionic polymerization88. Briefly, 4.6
mmol 1,1,1-trishydroxymethylpropane (THP) was partially deprotonated by the
addition of 1.5 mmol KOCH3 (25% in MeOH) under argon atmosphere at 95ºC for
30 min. The flask was evacuated for 30 min. The system was subsequently
refilled with argon, and 25 mL glycidol (x equiv.) was added by syringe pump
over 12 hours with stirring. The crude product was then dissolved in methanol,
and HPG was precipitated by the addition of acetone. HPG was purified by
repeating methanol/acetone precipitation (2x). To remove low molecular weight
HPG, HPG was dialyzed against DI water using 0.5-1kDa MWCO dialysis tubing.
The water was replaced twice every 12 hours. HPG was precipitated with
acetone and dried under vacuum at 80ºC for 12 hours.
PLA-HPG synthesis. PLA (5 g) and HPG (2.15 g) were dissolved in
dimethylformamide and dichloromethane (DCM) and dried overnight using 4Å
molecular sieves. Subsequently, 0.06 ml N,N’-diisopropylcarbodiimide (DIC) and
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10 mg 4-(N,N-dimethylamino)pyridine (DMAP) were added, and the mixture was
stirred at room temperature for 5 days. The product was precipitated by adding
the solution into cold ether. To purify the product, it was redissolved in DCM and
precipitated with cold ether. This precipitate was washed with the cold ether and
lyophilized for 2 days.
General methods for NP synthesis. PLA-HPG copolymer (50 mg) was
dissolved in 3 mL of solvent mixture (4:1 ethyl acetate:DMSO) with fluorescent
dye (DiD, 0.2 wt%) or drug (CPT, 10 wt%). The mixture was added to 4 mL DI
water under vortexing and subjected to probe sonication for 3 cycles of 10
seconds each. The emulsion was diluted in 10 ml DI water under stirring and the
solvent was evaporated with a rotavapor. The NP suspension was subsequently
filtered by centrifugation using an Amicon ultra centrifuge filters (100kDa
MWCO). The particles were washed twice with DI water, suspended in DI water,
and stored at -20ºC.
Conversion to BNPs. To convert NNPs to BNPs (Figure 3), one volume of
NNPs at 25 mg/ml was incubated with three volumes of 0.1M NaIO4 (aq) and one
volume of 10x PBS for 20 minutes. Three volumes of 0.2 M Na2SO3 (aq) were
added to quench the reaction. BNPs were washed two times with DI water using
Amicon ultra centrifuge filters (100kDa MWCO) and resuspended in DI water.
BNPs were stored at 4ºC.
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Figure 3. Incubation of non-bioadhesive PLA-HPG nanoparticles (NNP) with
NaIO4 produces an aldehyde-rich bioadhesive nanoparticle (BNP). The reaction
is quenched using Na2SO3, and formaldehyde is formed as a byproduct.
Encapsulated drug is illustrated as white circles within the nanoparticles.
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Assessment of NNPs and BNPs. To determine the concentration of NPs, a 100
µl aliquot of NP solution was placed in a pre-weighed 1.5 ml Eppendorf tube,
flash-frozen by incubation of the tube in liquid nitrogen, and lyophilized overnight.
The Eppendorf tube was subsequently weighed, and the initial weight of the tube
was subtracted to determine the weight of the NPs. The amount of DiD or CPT
encapsulated was determined by fluorescence. For quantification of CPT, one
volume of NPs was diluted in acidified DMSO, volume ratio 1:100 of 1N
HCl:DMSO (with SDS to assist dissolution of CPT). A standard curve was
prepared using known concentrations of CPT using the same assay. CPT
fluorescence was measured by fluorescence spectroscopy, with excitation at 370
nm and emission at 428 nm, and the loading concentration of CPT in NPs was
determined by comparison to the standard curve. For DiD, a standard curve was
also prepared, with excitation at 644 nm and emission at 665 nm.

Cell lines and cell culture
The PDV squamous cell carcinoma cell line (PDV) was obtained from
Allan Balmain (UCSF). PDV cells were maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS), 2% 1M Hepes, 1% 200mM Lglutamine, 1% 100mM sodium pyruvate, 1% 5 x 10-3 M 2-mercaptoethanol, 1%
10mM non-essential amino acids, and 1% 10,000 U/ml-µg/ml penicillinstreptomycin. Live cells were maintained at 37ºC and 5% CO2 in 25 cm2 or 125
cm2 Falcon tissue culture flasks (Thermo Fischer Scientific, Waltham, MA, USA).
Cells were harvested from flasks using 0.25% Trypsin-EDTA (Thermo Fischer

24
Scientific). For long-term storage, cells were resuspended in 90% FBS and 10%
DMSO and stored at -196ºC in a liquid nitrogen tank.

Confocal microscopy and image processing
All microscopy images were captured using the Leica TCS SP5 confocal
microscope. Images were processed using Fiji/ImageJ (NIH, Rockville, MD,
USA)89. Stacked images consist of images taken at 0.5-2 µm z-intervals. 3D
visualizations were constructed using Huygens Professional v17.04 (Scientific
Volume Imaging, Hilversum, Netherlands).

Flow cytometry data collection and analysis
Skin, tumor, and lymphatic cells were analyzed by flow cytometry as
described below. Samples were matched with the appropriate isotype controls.
Stratedigm S1000EX flow cytometer and CellCapture software v3.1 (Stratedigm
Inc., San Jose, CA, USA) were used to collect flow cytometry data. Data was
analyzed using FlowJo v10.4 (FlowJo LLC, Ashland, OR, USA).

Animal care and mouse tumor model
All animal procedures were performed in accordance with Yale
Institutional Animal Care and Use Committee (IACUC). Animals were kept in the
Yale Animal Resource Center and given free access to food and water
throughout the duration of the study. Mice were anesthetized in an induction
chamber using 30% isoflurane (Zoetis, Parsippany-Troy Hills, NJ, USA) in
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propylene glycol (Thermo Fischer Scientific). Mice were euthanized by overdose
in the same manner at the end of experiments.
Tumor transplantation. TCRβ-/- mice on the C57Bl/6J background were
obtained from The Jackson Laboratory (Bar Harbor, ME). To prepare the mice for
tumor transplantation, hair over the dorsal right flank was shaved with electric
clippers, and shaved skin was cleaned with an alcohol wipe. PDV cells were
harvested from tissue culture flasks. Cells were counted and then washed and
resuspended in ice-cold PBS at a concentration of 20 million cells/ml. Mice were
anesthetized prior to the procedure as described above. A subcutaneous
injection of 1 million cells/50 µl was placed using a 27.5-gauge syringe, forming a
small bleb at the site of injection.
Preparation for topical application. For topical application of DiD/NNPs,
C57Bl/6 mice were shaved using a straight razor blade while hair was in telogen
(resting) phase, at approximately 8-9 weeks of age. To minimize inflammation in
the skin, experiments were initiated 4-7 days after shaving.

In vitro PDV cell uptake of NPs
Cells were seeded at a density of 100,000 per 1.9 cm2 well in a 24-well
tissue culture treated plate (Corning, Inc.). At 24 hours after plating, media was
removed by glass pipette, and DiD/NNPs or DiD/BNPs were added at a
concentration of 0.01, 0.1, or 1.0 mg/ml in CRPMI. After 6 or 24 hours, cells were
washed with PBS and trypsinized. The enzymatic reaction was stopped by
addition of CRPMI. Cells were pelleted by centrifuge and washed twice with stain
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buffer (1x PBS, 1% FBS, 0.09% NaN3) and subsequent centrifugation. All
subsequent steps occurred on ice. Cells were then resuspended in surface block
containing anti-FcR (5 µg/ml), normal hamster IgG (11.8 µg/ml), and normal rat
IgG (22.2 µg/ml) and incubated for 15 minutes in a round-bottom 96-well plate
(Corning, Inc.). Cells were pelleted by centrifugation for 5 minutes at 1100 rpm at
4ºC, and supernatant was discarded. Pellet was resuspended in 100 µl of 2.5
µg/ml FITC anti-mouse CD326 Ep-CAM (BioLegend, San Diego, CA). After 25
minutes incubation, cells were centrifuged and washed twice with 250 µl stain
buffer. Cells were pelleted by centrifugation, and supernatant was removed. Cells
were resuspended in 100 µl of secondary antibody, 5 µg/ml Alexa-488-anti-FITC
(Life Technologies, Thermo Fischer Scientific) for 25 minutes. Centrifugation and
washing was repeated twice as described above. Cells were pelleted by
centrifugation and resuspended in 1% PFA for 20 minutes. Cells were
centrifuged and resuspended in PBS for short-term storage at 4ºC. Cells were
adhered to slides for visualization using the CytoSpin 4 Cytocentrifuge (Thermo
Fischer Scientific) 800 rpm for 5 minutes. Cells were mounted using ProLong
Gold Antifade Mountant with DAPI (Thermo Fischer Scientific) and a coverslip
was placed. Slides were kept in the dark at room temperature for 24 hours and
subsequently stored at -20ºC.

In vivo topical application
NNPs were thoroughly vortexed before use and diluted to 2 mg/ml using
DI water or 5% di(ethylene glycol) ethyl ether (Sigma) in DI water. Mice were
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anesthetized as described above. The rectangular area used for testing was
marked and measured on the dorsal back, ranging from 1-3 cm in each
dimension. NNPs were applied at a density of 2 µl/cm2 at a concentration of 2
mg/ml. The solution was allowed to dry on the skin for 5 minutes. A second coat
of NNPs was subsequently reapplied at the same density and allowed to dry for 5
minutes. The area was occluded using a non-stick bandage and secured in place
with tape. At the end point, mice were euthanized. The demarcated area of skin
was tape-stripped to remove excess dye on the surface and harvested. Tissue
was fixed in 4% methanol-free paraformaldehyde (PFA) for 48 hours and frozen
in Tissue-Tek OCT compound (Electron Microscopy Sciences, Hatfield, PA) for
sectioning.

Nanoparticle dispersion after intratumoral injection in vivo
Intratumoral injections. PDV tumors were transplanted as described above.
Tumors were measured using calipers three times per week beginning 1 week
after transplantation. To determine where nanoparticles disperse after
intratumoral injection, we injected 100 µl DiD/NNP intratumorally and used flow
cytometry to measure fluorescence in individual cells of the tumor and draining
inguinal lymph node as described below.
Materials. DNAse was prepared by reconstituting 10 million Dornase units
(ICN#190062) in a mixture of 1 ml 10x DNAse buffer, 4 ml sterile distilled water,
and 5 ml glycerol. Aliquots of DNAse were stored at -20ºC. Media A was
prepared with 100 ml MEM (Gibco, Thermo Fischer Scientific), 10 ml FCS, 1 ml
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100x pencillin-streptomycin, and 50 µl DNAse, and stored at 4ºC. Trypsin-GNK
was prepared by adding the following to 1700 ml of dH2O: 14.7 g NaCl, 0.7 g
KCl, 1.7 g glucose, and 5.0 g Trypsin (Sigma T-1005). The pH was adjusted to
7.6 using NaHCO3, and the solution was filter sterilized. Trypsin-GNK aliquots
were stored at -20ºC. Personna single-edge surgical prep razor blades were
obtained from AccuTec Blades Inc. (Verona, VA, USA). Dermis Digestion buffer
was prepared fresh by mixing the following into RPMI: 2.7 mg/ml collagenase
(Sigma), 0.25 mg/ml hyaluronidase (Sigma), 10 µl/ml DNAse, 10 µl/ml 1 M
HEPES (Gibco), and 10 µl/ml 100x sodium pyruvate (Gibco). Nalgene™ RapidFlow™ 0.2 µm PES membrane. Petri dishes and centrifuge tubes were obtained
from Corning, Inc. (Corning, NY, USA).
Tissue harvesting. Mice were euthanized and affixed to a Styrofoam board. The
skin of the mice was soaked with 95% ethanol, covering all areas to be
manipulated during tissue harvesting. Hair was removed over the site of the
tumor using surgical prep blades. With the mouse in the supine position, a
midline cut in the skin was made, running superiorly from the groin to the neck
using scissors. Subsequent cuts were made bilaterally from the groin to the inner
hind legs, creating flaps on each side of the abdomen that were then pulled
outward and affixed to the board. Inguinal lymph nodes, found on these skin
flaps, were then dissected away from subcutaneous fat using forceps. Lymph
nodes were placed in a dish of Media A on ice. With the mouse in the prone
position, the tumor and skin overlying the tumor were resected and prepared as
described below. For flow cytometry experiments, the skin was separated from
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the tumor. For assessment of histology by confocal microscopy, the skin and
tumor were remained attached by subcutaneous fat and/or adhesions.
Epidermal and dermal cell preparation. Skin was placed on a petri dish lid with
the epidermis facing down and was spread out until flat. Subcutaneous fat was
removed by scraping the dermal side using the dull edge of a pair of closed
scissors. A surgical prep blade was then used to cut the skin into approximately 1
cm wide strips. Strips of skin were placed dermal side down in a petri dish
containing Trypsin-GNK (T-GNK). The dish was covered and incubated for 2 hr
at 37°C. Fine forceps were then used to separate the epidermis from dermis. To
digest the epidermis, all epidermal strips from a single mouse were collected and
in 50 ml tube containing 8 ml T-GNK, 2 ml RPMI, and 50 µl DNAse. Tubes were
incubated in a 37°C shaking water bath for 10 minutes. Tubes were removed
from the water bath, and 10 ml Media A was added to each tube. Digested tissue
was filtered through 70 um Nitex mesh into a new 50 ml Falcon tube to remove
stratum corneum, hairs, and other large debris. Cells were centrifuged and
washed with Media A. To digest the dermis, the tissue was first minced in Petri
dish containing Dermis Digestion Buffer. Tissue was incubated for 1-1.5 hr at
37°C with occasional mixing using serological pipet to break up clumps. The
digested mixture was filtered through 70 µm Nitex nylon mesh to remove any
remaining large pieces of tissue. Media A was added to stop digestion of tissue,
and cells were washed twice with Media A. For some experiments, epidermal
and dermal cells were pooled for analysis.
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Lymph node cell preparation. The rough area of two frosted microscope slides
(Thermo Fischer Scientific, Waltham, MA, USA) were dipped in a petri dish
containing Media A to remove dust. Using forceps, lymph nodes were placed on
the frosted area of one slide and covered with the frosted area of the second
slide. The two slides were gently rubbed together to break apart the lymph nodes
and allow the cells to separate, and free cells were washed into the petri dish
from the slide. The media containing lymph node cells was collected and filtered
through sterile 70 µm Nitex nylon mesh into a 15 ml Falcon tube. Cells were
centrifuged for 8 minutes at 1100 rpm, before resuspension in Media A. The cells
were placed on ice.
Spleen preparation. The spleen was minced in Media A using ethanol-sterilized
scissors. The media was collected and filtered using a 70 um Nitex mesh into a
15 ml Falcon tube. The collected cells were centrifuged for 8 minutes at 1100
rpm and resuspended in 5 ml ACK lysis buffer. After incubation for 4 minutes, the
tube was filled with Media A and centrifuged for another 8 minutes. The pellet
was resuspended in Media A and placed on ice.
Tumor cell preparation. Each tumor was placed in a 60-mm petri dish
containing collagenase/hyaluronidase buffer and minced using ethanol-sterilized
scissors. The tissue was incubated at 37°C for 1.5-2 hr with occasional mixing
with serological pipet to break up larger pieces of tissue. Liquid from the dish was
moved to a 15 ml Falcon tube, and Media A was added to stop digestion. The
suspension was filtered using 70 um Nitex into a new 15 ml Falcon tube. The
remaining undigested pieces of tissue were incubated with T-GNK at 37°C for
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1.5-2 hr with occasional mixing, until the majority of tissue was digested. Media A
was added to stop the digestion, and the cell suspension was filtered through a
70 um Nitex mesh. Cells were pelleted by centrifugation and resuspended in a
small amount of Media A for counting and placed on ice. The
collagenase/hyaluronidase-digested cells and the T-GNK digested cells were
pooled for analysis.
Cell type staining. Cells were counted using a Neubauer Ruled hemocytometer.
Up to 1 million cells were aliquoted per FC sample. Cells were resuspended in 50
µl/sample of ice-cold block (stain buffer with anti-FcR (1:100) + normal hamster
IgG (1:500) + normal rat IgG (1:500)). Aliquots of 50ul/well were placed into a
round bottom 96-well plate on ice and covered with foil to minimize light
exposure. Ethidium monoazide bromide (EMA) at 2x concentration was prepared
in the dark by mixing 4 ml stain buffer and 2 ul of 2x EMA. For a final
concentration of 0.25 µl EMA/ml, 50 µl of 2x EMA was added to indicated
samples. The foil and plate cover were removed, and the plate was placed on ice
under a fluorescent lamp for 10 minutes. After light exposure, 150 µl of stain
buffer was added to each well. The plate was covered and centrifuged for 5
minutes. Supernatant was removed. Cells were resuspended in indicted primary
antibody diluted in stain buffer. The plate was covered in foil and incubated on
ice for 25 minutes. The plate was centrifuged and washed twice with stain buffer.
Cells were pelleted by centrifugation and resuspended in 1% PFA for 20 minutes.
Samples were centrifuged and resuspended in PBS before storage at 4ºC until
cytometry analysis.
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CPT nanoparticles in vitro
Cells were harvested from tissue culture flasks using 0.25% Trypsin-EDTA
as described above. Cells were washed using media containing 10% FBS, 1%
10,000 U/ml-µg/ml penicillin-streptomycin, and 10mM Hepes in HBSS. Cells
were resuspended in CRPMI and counted. Cells were centrifuged and
resuspended at 100 cells/µl and held on ice. Three-fold dilutions of CPT,
CPT/NNPs, and CPT/BNPs were prepared, with CPT concentration ranging from
0.002 µM to 15 µM. Cells were plated at a density of 5,000 cells per well in a flatbottom 92-well tissue culture clear bottom plate. At 24 hr after cell plating, the
prepared solutions of CPT, CPT/NNPs, CPT/BNPs, or DMSO (vehicle control) in
CRPMI were added to the wells. Cells were incubated at 37 ºC for 24, 48, or 72
hr. After incubation, the CellTiter-Glo® Luminescent Cell Viability Assay
(Promega, Madison, WI, USA) was used to determine cell viability based on the
quantity of ATP present in each well. Luminescence was read using the Victor
Light Luminescence Counter (Perkin Elmer, Waltham, MA, USA). Luminescence
was normalized to a vehicle control containing CRPMI and 3% DMSO, the
highest concentration of DMSO used in any sample.

Assessment of chemotherapeutic nanoparticle efficacy in vivo
PDV tumors were transplanted in mice as described above. In the pilot
experiment of 4 mice, tumors were injected with 0.5 mg CPT/100 µl of CPT/BNPs
at 23 days after tumor transplantation. This treatment was repeated at 1 week.

33
Control mice received two intratumoral injections of 100 µl PBS on the same
schedule. Subsequent experiments used a modified injection method to reduce
ulceration and minimize potential for systemic toxicity. In these experiments,
mice were treated with 0.125 mg CPT/50 µl of CPT/IL, CPT/NNPs, or CPT/BNPs
when the diameter of the tumor had reached 3 mm in any dimension. Injections
were repeated at a twice-weekly schedule. Injections were not performed on a
tumor if one of the following was true: (1) there was no identifiable tumor, or (2)
there was open ulceration at the site of a previous injection.
An 8 mm 31G insulin syringe (BD, Franklin Lakes, NJ, USA) was used for
intratumoral injections. NNPs and BNPs were vortexed and sonicated using a
Vibra Cell sonicator (Sonics & Materials, Inc.; Danbury, CT, USA) for 30 s before
use. Mice were anesthetized prior to the procedure. The needle was inserted
intratumorally such that the tip was positioned in the center of the tumor, and 50
µl of drug was slowly injected over approximately 15 seconds. The needle was
then held in this position for 10 seconds and slowly withdrawn to minimize
backflow. Gentle pressure was applied to the site of injection to prevent leakage.

Statistical analysis
Statistical analyses were conducted using Microsoft Excel 2016 for Mac
(Microsoft, Redmond, WA, USA) and Prism 7 (GraphPad, La Jolla, CA, USA).
Statistical significance between experimental groups was determined using twotailed Student’s t-tests for two-sample, equal variance datasets, with significance
at p < 0.05. Statistical significance between flow cytometry populations was
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determined by FlowJo (FlowJo LLC) using the Kolmogorov-Smirnov (K-S)
algorithm. The K-S algorithm is used to determine the confidence interval with
which it can be asserted that two univariate histograms are different.90,91 Notably,
for analysis of flow cytometry data, this method is most ideal for smaller
populations; with larger populations, there may be mathematical significance in
situations where there may not be biological significance.

Division of labor
Julia Lewis, PhD, and Patrick Monico performed all animal breeding and
genotyping. Hee-Won Suh, PhD, conducted polymer synthesis, nanoparticle
synthesis, and nanoparticle loading. NNP to BNP conversion was performed by
Emily Yin and Hee-Won Suh. Cell culture and cell viability experiments were
conducted by Emily Yin. Mouse injections and tumor measurements were
performed by Emily Yin and Alison Lee. Frozen tissue section preparation and
confocal microscopy were performed by Emily Yin. Formalin-fixed tissue was
paraffin embedded, sectioned and stained with H&E by the Yale
Dermatopathology Lab. Flow cytometry was performed by Emily Yin and Julia
Lewis.
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RESULTS
NP uptake by PDV cells in vitro
In order to assess NP association with SCC cells in vitro, we incubated
cells with fluorescent-dye loaded NNP or BNP and quantified fluorescence of
cells by flow cytometry. DiD/BNP had enhanced association with PDV SCC cells
compared with DiD/NNP in vitro (Figure 4). This relationship was consistent at
both 6 and 24 hours and at higher (1 mg/ml) and lower (0.1 mg/ml) NP
concentrations. A comparison of averaged median fluorescence intensities (MFI)
is also shown in Figure 4, in which ΔMFI represents the change in MFI between
6 and 24 hours. Table 1 displays p-value results for Student’s T-tests comparing
MFIs from each of the samples. Greater fluorescence was observed in samples
incubated with 1 mg/ml DiD/NNP and DiD/BNP compared with their respective
0.1 mg/ml samples. There was enhanced association of both DiD/NNP and
DiD/BNP with cells at 24 hours compared with 6 hours (Figure 4C).
Next, we sought to determine whether the association was due to NP
adhesion to the cell surface or whether NPs were being internalized by cells. By
confocal imaging, greater fluorescence in DiD/BNP-treated samples compared to
DiD/NNP-treated samples was consistently observed (Figure 5). When the EpCAM cell surface marker stain was used, DiD fluorescence was observed colocalizing with the surface stain in some areas and was also distributed inside the
cell membrane (Figure 5B-C), suggesting that NPs both adhere to the cell
surface and are internalized by cells.
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Figure 4. Bioadhesive nanoparticles (BNP) showed superior association
with PDV squamous cell carcinoma cells relative to non-bioadhesive
nanoparticles (NNP). Cells were harvested and analyzed by flow cytometry at
(A) 6 hours and (B) 24 hours after co-incubation with 0.1 mg/mL or 1 mg/mL
fluorescent dye-loaded NNP or BNP.
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Table 1. Results of Student’s T-test (two-tailed, two-sample equal variance)
indicates increased association of BNP compared to NNP with cells at both
time points, and increased association of dye particles at 24 hours
compared with 6 hours for both NNP and BNP samples. (A) Comparison of
non-bioadhesive nanoparticles (NNP) and bioadhesive nanoparticles (BNP)
samples at each combination of time-point and concentration. (B) Comparison of
6-hour and 24-hour samples for NNP and BNP at each concentration.

(A)
Time-point

NP Concentration

NNP vs. BNP
P-value

6 hours

1 mg/ml

0.000051

6 hours

0.1 mg/ml

0.000053

24 hours

1 mg/ml

0.000071

24 hours

0.1 mg/ml

0.000163

NP Concentration

6 hr vs. 24 hr

(B)
Sample

P-value
NNP

1 mg/ml

0.000090

NNP

0.1mg/ml

<0.0000001

BNP

1 mg/ml

0.000060

BNP

0.1mg/ml

0.000226
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Figure 5. Confocal microscopy shows particle-encapsulated fluorescent
dye (red) inside PDV squamous cell carcinoma cells after 24-hour culture.
(A) Control, DiD/NNP, and DiD/BNP samples displayed as stacked images. (B)
Image montage shows cross-sections at 0.5 µm intervals through the thickness
of the cells. (C) Cells at higher power show dye-loaded NNP observed both
inside the cell and on the surface (co-localizing with Ep-CAM).
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Analysis of DiD/NNP distribution in cells after topical application
To determine the distribution of NPs after topical application, we applied
DiD/NNP to the shaved skin of mice and assessed skin by confocal microscopy.
While BNPs would be expected to remain on the surface due to their bioadhesive
properties, we hypothesized that NNPs would absorb into the skin and therefore
be a better mode of chemotherapeutic drug delivery. DiD/NNP suspended in 5%
di(ethylene glycol) ethyl ether was applied topically to shaved skin on the flanks
of mice and occluded with a band-aid in order to visually assess the dispersion of
NPs after topical application. With the goal of maximizing nanoparticle
penetration through the epidermis, di(ethylene glycol) ethyl ether was selected as
a solvent, as it is commonly used to increase epidermal drug penetration. Frozen
sections were assessed qualitatively by confocal microscopy (Figure 6).
The distribution of DiD/NNP after topical application was further assessed
by flow cytometry of harvested skin cells (Figure 7). Langerhans cells were
gated on CD45+, MHC II+, and CD3-; T-cells were gated on CD45+, CD3+, and
MHC II- (Supplemental Figure S1). There was an increased association of
DiD/NNP with Langerhans cells in the epidermis compared to DiD alone and
control (K-S >99.9%) (Figure 7A). Similarly, there was an enhanced association
of DiD/NNP with T-cells in the epidermis (K-S >99.9%) (Figure 7B). CD45- cells
from the epidermis (Figure 7C), largely representing keratinocytes, also showed
improved association with DiD/NNP (K-S >99.9%), as did CD45- cells from the
dermis (K-S >99.9%) (Figure 7D). The T(X) values indicate that in each subset
of cells, the DiD/NNP and control populations were statistically different.
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Figure 6. Confocal microscopy shows accumulation of dye-loaded nonbioadhesive nanoparticles (red) suspended in 5% di(ethylene glycol) ethyl ether
in the epidermis and hair follicles. Nuclei are stained with DAPI (blue). (A) Control
(no topical application). (B) 4 hours after topical application; higher power at right.
(C) 72 hours after topical application; higher power at right.
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Figure 7. Topical application of DiD dye-loaded non-bioadhesive nanoparticles
(NNPs) on the skin of mice results in enhanced association of dye with
epidermal, dermal, and local immune cells compared to DiD application alone.
Fluorescence of PDV squamous cell carcinoma cells was measured by flow
cytometry 72 hours after topical skin application of DiD or DiD/NNP. (A)
Langerhans cells (CD45+ MHC II+ CD3-) in the epidermis. (B) T-cells (CD45+
CD3+ MHC II-) in the epidermis. (C) CD45- cells in the epidermis. (D) CD45cells in the dermis. Each plotted curve represents data from one mouse. Control
populations represent mice that received injections of an equal volume of 1x
PBS. Median fluorescence intensity (MFI) for each sample is shown in the
corresponding tables. ΔMFI refers to the change in MFI between each sample
and the control.
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Distribution of DiD/BNP after intratumoral injection
To assess the distribution of BNPs after intratumoral injection, we injected
100 µl of DiD/BNP into established PDV tumors at 4 weeks after tumor
transplantation. We harvested the tumors after 72 hours and digested the tissue
for analysis of fluorescence by flow cytometry. We also harvested the draining
inguinal lymph node to address the potential for targeting immune cells. Gating of
defined cell populations is shown in Supplemental Figure S1. Flow cytometry
demonstrated significant association of DiD/BNP with a variety of cell types
harvested from the draining lymph node, tumor, and skin (Figure 8). Comparing
CD45- tumor cells, the treated samples were significantly different from the
control (K-S >99.9%). The subset of CD45+ cells from the tumor was also
assessed to determine the association of particles with local, tumor-associated
immune cells, with increased fluorescence seen in the treated sample (KS >99.9%). There was also a difference between treated and untreated samples
of CD45+ cells from the draining lymph nodes (K-S >99.9%).
To visualize the anatomical distribution of NPs after intratumoral
injections, DiD/BNP injections were repeated on another tumor for analysis by
confocal microscopy. Imaging of frozen sections of these tumors showed
fluorescent dye throughout the tumor, indicating tumor-wide penetrance of the
intratumoral injection (Figure 9).
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Figure 8. At 72 hours after intratumoral injection of 100 μL fluorescent dyeloaded bioadhesive nanoparticles, there was significant association of
nanoparticles with cells harvested from the tumor and draining lymph node
as assessed by fluorescence on flow cytometry. (A) CD45- cells from tumor.
(B) CD45+ cells from tumor. (C) CD45+ cells from lymph node.

45
Figure 9. After intratumoral injection of 100 µl of fluorescent dye-loaded
bioadhesive nanoparticles, nanoparticles were visualized by confocal to be
distributed throughout the tumor. Concentration of nanoparticles within injected
tumors was variable. (A) Nanoparticles were observed dispersed throughout the
imaged area of a tumor. (B) Images from another injected tumor show
nanoparticle dispersion throughout the layers of the skin and tumor, from minimal
dye visibility in the epidermis (top) to the highly saturated tumor (bottom).
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Cytotoxicity of CPT, CPT/NNP, and CPT/BNP in vitro
To compare the cytotoxic efficacy of our delivery methods in vitro, we
used the CellTiter-Glo® Luminescent Cell Viability Assay (Promega) to measure
cell viability after treatment of PDV cells with CPT, CPT/NNP, or CPT/BNP.
Cytotoxicity assays were conducted at 24, 48, and 72 hours of incubation with
the drug (Figure 10). At these time points and the selected range of
concentrations, the viability curve of paclitaxel was not well visualized. NP
encapsulation was attempted for each drug. However, only CPT was
successfully encapsulated in PLA-HPG, and therefore this drug was used for
subsequent experiments.
The time-point selected for further study was 48 hours, due to the ability to
visualize the full viability curve of CPT at this time. To compare NP-encapsulated
drug with drug alone, cells were incubated with CPT, CPT/NNP, or CPT/BNP for
48 hr. The three treatments had similar effects on cell viability (CPT IC50=0.2770
[95% CI: 0.2365, 0.3246]; CPT/NNP IC50=0.4283 [0.3387, 0.5423]; CPT/BNP
IC50=0.1708 [0.1444,0.2020] (Figure 11). Although statistically different, it is not
clear from this experiment whether the difference has biological or clinical
significance.
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Figure 10. PDV cells were incubated with paclitaxel or camptothecin to
assess the cytotoxicity and IC50 of each drug. Cell viability was measured by
CellTiter-Glo® Luminescent Cell Viability Assay (Promega) at (A) 24, (B) 48, and
(C) 72 hours.
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Figure 11. Incubation of PDV cells with camptothecin-loaded non-adhesive
nanoparticles (CPT/NNP) resulted in slightly increased cell death at 48
hours compared to incubation with camptothecin (CPT) or CPT-loaded
bioadhesive nanoparticles (CPT/BNP). Cell viability was measured by the
CellTiter-Glo® Luminescent Cell Viability Assay (Promega). The three treatments
had statistically different IC50 values: CPT IC50=0.2770 [95% CI: 0.2365, 0.3246],
CPT/NNP IC50=0.4283 [0.3387, 0.5423], CPT/BNP IC50=0.1708 [0.1444,0.2020].
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Efficacy of CPT, CPT/NNP, and CPT/BNP in treating PDV SCC tumors
In a small pilot study (n=4), mice with established PDV tumors were
treated with intratumoral injections of CPT/BNP or 1x PBS to determine the
efficacy of CPT/BNP in vivo. Control mice treated with 1x PBS injections showed
significant, rapid tumor growth over 4 weeks of observation, while complete
resolution of the transplanted tumor was seen in all CPT/BNP treated mice (n=2)
(Figure 12). Tumors were harvested and fixed in 4% PFA for sectioning, and
sections were stained with H&E. Large tumors were confirmed by histology in
both of the control mice (Figure 12C), while no tumors were observed by
histological examination in the two CPT/BNP-treated mice (Figure 12D).
Given concern for potential systemic toxicity, we used a lower dose of
CPT and increased frequency of treatments in our subsequent study. We also
compared CPT/BNPs to CPT in an intralipid 20% vehicle (CPT/IL) and
CPT/NNPs. The dose of CPT was reduced from 0.500 mg to 0.125 mg per
injection, while the frequency of injections increased from weekly to twice per
week. This study (n=25) showed efficacy of all three CPT-containing treatment
groups. Figure 13 shows the Kaplan-Meier survival analysis for each group, in
which the endpoint represents the tumor reaching a diameter greater than or
equal to 1.0 cm in any direction. Each of the three CPT-containing samples
(CPT/IL, CPT/NNP, CPT/BNP) was significantly different compared to the IL-only
control (p=0.013, 0.002, 0.002, respectively). There was no statistical difference
in the Kaplan-Meier survival analyses among CPT/IL, CPT/NNP, and CPT/BNP
(p(CPT/IL v. CPT/NNP) = 0.1259; p(CPT/IL v. CPT/BNP) = 0.1744; p(CPT/NNP v. CPT/BNP) =
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0.9091). However, there was a trend toward significance in comparing CPT/NNP
and CPT/BNP samples with CPT/IL, suggesting that CPT/NNP and CPT/BNP
may have enhanced antitumor effects. In addition, examination of the histology of
the tumors suggested that external tumor measurements in the CPT/NNP and
CPT/BNP groups may over-estimate the actual tumor burden due to increased
necrosis compared to CPT/IL-treated mice.
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Figure 12. In a pilot study of mice with transplanted PDV tumors (N=4), tumors
were treated with two weekly intratumoral injections of 0.5 mg/100 µl
camptothecin bioadhesive nanoparticles (CPT/BNP) or 1x PBS (control). While
control mice showed rapid tumor growth over the 3 weeks after initiation of
treatment (A, C), tumors treated with CPT/BNP had complete resolution of their
tumors (B, D). Images are from 10 days after final injection.
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Figure 13. Kaplan-Meier survival analysis indicated a significant difference in
time to 1 cm between the intralipid 20% (IL) control and each of the CPT groups:
CPT in IL (CPT/IL), CPT/NNP, and CPT/BNP (N=20). Survival of CPT/IL
(p=0.013), CPT/NNP (p=0.002), CPT/BNP (p=0.002) were significantly different
compared to the control. No significant difference was observed between the
three CPT treatment groups (p(CPT/IL v. CPT/NNP) = 0.1259; p(CPT/IL v. CPT/BNP) = 0.1744;
p(CPT/NNP v. CPT/BNP) = 0.9091). Mice received twice weekly intratumoral injections
containing 0.125 mg CPT in a 50 µl volume. A treatment was skipped if either of
the following were true: (1) ulceration at the site of injection, or (2) tumor was
neither visible nor palpable.
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DISCUSSION
Polymer NPs can be employed as an effective drug delivery system and
may be particularly well-suited for the treatment of malignant tumors. Given the
limitations of current treatments in skin cancer, NPs provide a delivery method for
chemotherapeutic agents that may improve treatment efficacy and decrease the
risk of tumor recurrence. This is the first study to assess the efficacy of NPencapsulated chemotherapeutic agents in the treatment of skin cancer. Our
preliminary results demonstrate the efficacy of PLA-HPG NPs in the delivery of
CPT for the treatment of SCC in mice.
As we had hypothesized based on prior studies, BNPs showed an
increased association with PDV cells compared with NNPs. This can be
explained by the aldehyde-rich surface chemistries of BNPs, which facilitate
covalent bonding to cellular proteins. We not only observed the association of
dye-loaded NPs with cells, but also confirmed internalization of NPs by PDV cells
via confocal microscopy. The latter further suggested that NPs, in particular
BNPs, may be effective at directly targeting malignant cells. While a specific
mechanism of uptake has not been described for PLA-HPG NPs, prior studies
suggest that a number of different pathways may be at work. For instance, PLAPEG NPs have been shown to be taken up by receptor-mediated endocytosis.92
Macropinocytosis has also been implicated as a pathway of internalization for
other classes of NPs.93 The predominant method of uptake may also depend on
cell type and local environment.
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Our observation of significant fluorescence in both NNP- and BNP- treated
samples at 6 hours suggests that an NP-based delivery method could rapidly
begin targeting tumor cells within hours. The increased association at 24 hours
also provides evidence of the continued capacity of PDV cells to associate with
NPs with prolonged co-incubations and lends support to the depot effect
advantage of NPs. Additional studies at longer time-points may help determine
when and at what concentration a plateau in NP association with cells is
reached. This may help determine the ideal concentration of NP for therapeutic
use in order to maximize treatment efficacy.
We also found that after topical application of NNPs, there was significant
penetration of particles through the full thickness of the epidermis as well as in
hair follicles, by as early as 4 hours and persisting for at least 72 hours. There
was enhanced uptake of NNPs by cells compared to fluorescent dye alone,
including in keratinocytes in the epidermis, fibroblasts in the dermis, and T-cells
and Langerhans cells in the epidermis. This supports the use of NNPs as a
topical delivery method and also suggests NPs may be an effective delivery
system for immune-modulating therapies. Notably, the K-S algorithm was used to
determine whether there were statistical differences in fluorescence between
these populations of cells. While this statistic is recommended for comparing
populations, it is notably a measure of mathematical and not biological
difference. As the value of n increases, particularly in our flow cytometry data that
has populations in the thousands to hundreds of thousands, there is an
increasing likelihood of a >99% difference between two populations. As such,
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while we can conclude that there is a true difference in the association of
DiD/NNPs and DiD alone with T-cells, Langerhans cells, epidermal keratinocytes,
and connective tissue cells in the dermis, the biological or clinical significance of
these findings is more subjective. However, we can compare the relative impact
of NNP delivery on various cell types by comparing the ΔMFI of various cell
types. For instance, Langerhans cells (ΔMFI=7.24), T-cells (ΔMFI=6.1), and
epidermal keratinocytes (ΔMFI=5.25) have greater uptake of NNPs compared to
dermal fibroblasts (ΔMFI=1.93).
Despite the difference in surface chemistry between NNPs and BNPs, and
the related difference in cell association, there was only a small difference in
effect on cell viability among CPT/NNP, CPT/BNP, and CPT in vitro. CPT/NNP
had the lowest IC50, while CPT/BNP had the highest IC50, and thus a higher
concentration of CPT/BNP would be necessary to achieve the same degree of
cytotoxicity. This may appear contrary to our previous findings that BNPs have
preferable association with PDV cells compared to NNPs; however, association
with NPs is not necessary for the drug to exert its cytotoxic effects, as freefloating NPs will continue to release active CPT. In addition, while these results
were statistically different, their clinical significance is less clear. Taken together,
these findings may also suggest that the lack of cytotoxic advantage of CPT/BNP
compared to CPT/NNP is not related to the degree of NP-cell kinetics, but rather
may be explained by drug-cell or drug-NP kinetics. Previous studies using CPT in
PLA-HPG nanoparticles have shown that at room temperature in buffered water,
the particles release slightly over half of their contents within 24 hours, and the
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remaining encapsulated drug is released over a period of 1 week.60 However,
this release profile may not be applicable for in vitro studies in buffered cell
media at 37ºC. Drug may be released more quickly in these conditions, thereby
minimizing the advantages conferred by NP encapsulation. While less likely, it is
also possible that the nanoparticles may degrade and release CPT more slowly
in these settings, such that an incubation time longer than 48 hours would be
necessary to observe differences between NNPs and BNPs. Previous studies
from our research group have suggested that a difference in antitumor efficacy
between delivery methods may be observed only in in vivo studies, while no
difference is observed in vitro. Deng et al. showed that PLA-HPG CPT/NNP
significantly decreased tumor burden in Lewis lung carcinoma-bearing mice
compared to PLA-PEG CPT/NNP, however no difference in cytotoxic efficacy
was seen between the PLA-HPG and PLA-PEG CPT/NNP in vitro.60
Our initial in vivo pilot study also demonstrated the efficacy of CPT/BNP in
the treatment of established SCC tumors. Due to concern for potential systemic
toxicity associated with such a high dose of CPT, we used a decreased dose and
increased frequency of treatments in our subsequent study. In this second
experiment, several mice received fewer than the scheduled biweekly doses, as
injections were not administered if the mice had ulceration from prior injections or
in the absence of a visible or palpable tumor. Given the absence of complete
resolution in the tumors in this experiment, a higher dose of CPT is likely
necessary to definitively treat these tumors.
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Furthermore, our study demonstrated that CPT/NNP and CPT/BNP may
be more effective in the treatment of established PDV SCC tumors compared to
CPT/IL. In our Kaplan-Meier analysis, there was a trend towards superiority of
CPT/NNP and CPT/BNP compared to CPT/IL (p(CPT/IL v. CPT/NNP) = 0.1259; p(CPT/IL v.
CPT/BNP)

= 0.1744). We had hypothesized that both NNPs and BNPs would have

superior antitumor efficacy compared to drug alone. As previously described,
polymer NPs are notable for the advantages of gradual release and producing a
depot effect, as well as advantages secondary to the EPR effect. Thus, the lack
of statistical difference between NP-encapsulated drug and drug alone may
suggest an insufficient sample size, or it may point to these NP advantages
having been minimized or hindered by another process. As previously proposed,
immediate release of drug from the particles after intratumoral injection may
decrease advantages in efficacy expected from controlled-release. Injection of a
relatively large volume of drug into the tight space of the tumor interstitium may
cause structural changes to the tissue, vasculature, or lymphatic drainage that
minimize the EPR effect which gives NPs their antitumor advantage.
In addition, we had hypothesized that CPT/BNP would have superior
efficacy compared to CPT/NNP due to BNPs’ enhanced ability to bind to cellular
proteins and increased uptake in vivo. This pattern was seen in prior studies of
glioblastoma and intraperitoneal uterine serous carcinoma from our group.
However, in glioblastoma, the continual flow of CSF through the brain may make
NNPs easily cleared away, while in the case of intraperitoneal carcinomas,
intraperitoneal fluid is also absorbed and replenished over time. Relative to these

58
tumor models, there is likely relatively limited drainage from the self-contained
PDV SCC tumors. As described in the EPR effect, lymphatics in tumors have
poor drainage, and in such a setting, NNPs and BNPs may be similarly retained
in the tumor interstitum. Future studies may employ dye-loaded NPs to compare
the degree to which NNPs and BNPs track to the draining lymph nodes. While
we believe that NP delivery has advantages that can be exploited to improve the
treatment of cutaneous malignancies, our preliminary data has not been able to
definitively confirm this hypothesis.
Our study has a few limitations. First, when visualizing dye by confocal
microscopy, we cannot be certain that we are visualizing only NPs and not free
dye that has been released from NPs. Similarly, we know that drug release from
NPs is dependent on the encapsulated drug, therefore the behavior of dyeloaded NPs may not be highly predictive of CPT-loaded NPs. Another limitation
is the potential for human bias or variation in our procedures. Our studies were
not blinded, as they were in large part conducted by a single researcher in an
effort to minimize researcher-to-researcher variation in injection and
measurement techniques. When injecting tumors that may range significantly in
size, shape, and density, it is impossible to fully standardize injection techniques.
However, we sought to replicate our injection technique as precisely as possible
from mouse to mouse. Finally, the external measurement of tumors may be
complicated by inflammation and necrosis that occurs secondary to treatment.
Histological examination of tumors suggested that tumor burden may be overestimated in NNP-treated and BNP-treated mice due to widespread necrosis.
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Additional studies are underway to optimize the concentration and
frequency of drug delivery in order to consistently and definitively treat tumors.
Future experiments will also aim to assess other potential injection techniques to
determine the most effective means of delivering our treatment. Other
chemotherapeutic drugs will be tested, as they may offer increased efficacy for
our tumor model. While paclitaxel was difficult to encapsulate in PLA-HPG NPs,
other types of polymers may be better suited for encapsulating the drug.
Epithilone B has also been found effective in a number of other murine studies,
including in uterine serious carcinoma, and has been encapsulated in PLAHPG.79 While our current tumor model employs subcutaneous tumors, we may
also study NP efficacy in other tumor models, such as chemically induced tumors
via topical application of DMBA and TPA. For these models, cutaneous
application of treatments may be used in conjunction with other delivery
methods, such as microneedles, ultrasound, or tape-stripping.94
Aside from directly targeting malignant tumor cells, the local immune
system may also be an effective target for antitumor therapies. Our study found
significant NP uptake both in Langerhans cells and T-cells in the local tumor
environment, as well as in cells in the draining lymph node. Immune-stimulating
drugs, such as imiquimod or interferons, may therefore be effectively delivered
by NP encapsulation. Imiquimod is currently used as a topical therapy to
stimulate the local immune system to attack tumor cells; encapsulation in NPs
may prolong and enhance the effects of the drug. Additionally, co-encapsulation
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simultaneous administration with a chemotherapeutic drug or may produce an
additive or synergistic effect.
In addition to the potential of NP delivery in the treatment of cutaneous
malignancies, NP encapsulation can also enhance existing preventative skin
cancer strategies. Our research group recently developed a novel, BNP-based
sunblock that enhances duration of protection and minimizes the production of
reactive oxygen species typically associated with chemical UVR-blocking
agents.95 These benefits are a result of BNPs engineered for minimal release of
drug over time and adherence to the stratum corneum. We also plan to use our
NP delivery platform to provide post-UV protection in the form of antioxidants and
“triplet-state quenchers” to counteract free radicals and oxidative stress that can
lead to DNA damage hours after sun exposure.96
In conclusion, our study demonstrates that polymer-based NPs are a
promising drug delivery system for chemotherapeutic treatment of skin cancer,
and that CPT/BNPs may have the capacity to definitively treat PDV SCC. While
surgery will likely remain an important therapy for skin cancer, an NP-based
treatment may offer an improved therapeutic option for patients with lesions
affecting large surface areas or who are otherwise poor candidates for surgical
therapy. NP delivery may also allow post-surgical treatment in the surgical bed to
prevent recurrence and eliminate any remaining cancer cells. Through these
methods, NP encapsulation may enhance the prevention and treatment of skin
cancer, offering superior efficacy when compared to existing preventative and
therapeutic methods.
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SUPPLEMENTAL APPENDIX

Figure S1. Sample gating for flow cytometry data shows how cell types were
defined. (A) Gating of epidermal cells for viability (EMA-); myeloid lineage
(CD45+); and Langerhans cells (CD45+, CD3+, MHCII-) or T-cells (CD45+,
CD3-, MHCII+). (B) Gating of tumor cells for viability (EMA-) or myeloid lineage
(CD45+).

